Journal Watch · Frontiers in Immunology · 2026

Upadacitinib for refractory generalized lichen sclerosus: a case report and brief literature review.

This case supports the effectiveness of upadacitinib in refractory generalized LS and offers a brief review of relevant literature.

Xiao M, Li J, Wei Z et al.Frontiers in Immunology3 min readPharma relevance 50/100

DOI: 10.3389/fimmu.2026.1873990PMID: 42459671Study type: review / perspective

TL;DR

This case supports the effectiveness of upadacitinib in refractory generalized LS and offers a brief review of relevant literature.

Key findings

  • During the 10-month follow-up period, pruritus was significantly alleviated, and skin sclerosis as well as atrophic patches showed marked improvement.
  • No new blisters or skin lesions emerged, and no severe adverse reactions were observed.
  • This case supports the effectiveness of upadacitinib in refractory generalized LS and offers a brief review of relevant literature.

What they did

The highly selective JAK1 inhibitor upadacitinib demonstrates robust efficacy across various inflammatory dermatoses; however, reports of its application in LS remain scarce. Herein, we report the case of a 62-year-old female patient with refractory generalized LS who presented with a 2-year course. The skin lesions involved the trunk, extremities and vulvar region, and failed to respond to multiple conventional treatments. Upadacitinib at a dose of 15 mg daily was administered to the patient.

Full abstract (original)

Background: Lichen sclerosus (LS) is a chronic, lymphocyte-mediated inflammatory skin disease characterized by porcelain-white atrophic skin lesions. Localized LS is relatively common and predominantly occurs in the anogenital region. Generalized LS involving both genital and extragenital sites is clinically rare and frequently refractory to conventional therapies like topical corticosteroids. As an emerging targeted therapy, Janus kinase (JAK) inhibitors demonstrate broad therapeutic potential.

What they did: The highly selective JAK1 inhibitor upadacitinib demonstrates robust efficacy across various inflammatory dermatoses; however, reports of its application in LS remain scarce. Herein, we report the case of a 62-year-old female patient with refractory generalized LS who presented with a 2-year course. The skin lesions involved the trunk, extremities and vulvar region, and failed to respond to multiple conventional treatments. Upadacitinib at a dose of 15 mg daily was administered to the patient.

Results & conclusions: During the 10-month follow-up period, pruritus was significantly alleviated, and skin sclerosis as well as atrophic patches showed marked improvement. No new blisters or skin lesions emerged, and no severe adverse reactions were observed. This case supports the effectiveness of upadacitinib in refractory generalized LS and offers a brief review of relevant literature.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1873990 · PubMed 42459671.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

This case supports the effectiveness of upadacitinib in refractory generalized LS and offers a brief review of relevant literature.

What type of study is this?

It is a review / perspective, published in Frontiers in Immunology in 2026. The highly selective JAK1 inhibitor upadacitinib demonstrates robust efficacy across various inflammatory dermatoses; however, reports of its application in LS remain scarce.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1873990. PubMed ID: 42459671. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Xiao M, Li J, Wei Z et al.. Upadacitinib for refractory generalized lichen sclerosus: a case report and brief literature review.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1873990.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/upadacitinib-for-refractory-generalized-lichen-sclerosus-a-case-report-a-873990/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides